Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label 4-year ocrelizumab study in progressive multiple sclerosis
2017-001313-93Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: No evidence of progression (NEP) sustained for at least 24 weeks. Started Feb 2018; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2017-001313-93.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001313-93.